We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Drug Use Investigation for REVOLADE (ITP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01416311
Recruitment Status : Active, not recruiting
First Posted : August 15, 2011
Last Update Posted : March 29, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy.

<Priority investigation item> Thromboembolism


Condition or disease Intervention/treatment
Purpura, Thrombocytopaenic, Idiopathic Drug: Eltrombopag

Study Design

Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)
Study Start Date : December 2010
Estimated Primary Completion Date : December 27, 2018
Estimated Study Completion Date : December 27, 2018


Groups and Cohorts

Group/Cohort Intervention/treatment
Subjects prescribed REVOLADE
Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
Drug: Eltrombopag


Outcome Measures

Primary Outcome Measures :
  1. The number of subjects with any adverse events treated with REVOLADE [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Appearance of thromboembolism [ Time Frame: 1 year ]
    If thromboembolism is appeared or not in subjects who received REVOLADE will be investigated throughout the study period


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All Japanese subjects with chronic idiopathic thrombocytopenic purpura who recieve REVOLADE
Criteria

Inclusion Criteria:

  • Subjects with chronic idiopathic thrombocytopenic purpura

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01416311


Sponsors and Collaborators
Novartis
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
More Information

Responsible Party: Novartis
ClinicalTrials.gov Identifier: NCT01416311     History of Changes
Other Study ID Numbers: 114877
First Posted: August 15, 2011    Key Record Dates
Last Update Posted: March 29, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Purpura
Purpura, Thrombocytopenic, Idiopathic
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Thrombocytopenia
Blood Platelet Disorders
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases